After deliberating for seven hours, a state court jury in Philadelphia found Tuesday that GlaxoSmithKline failed to properly warn doctors and pregnant women about risks associated with its blockbuster antidepressant Paxil. The jury awarded $2.5 million in damages to the family of Lyam Kilker, who was born with heart defects after his mother took Paxil during her pregnancy. We wrote about the start of the trial here.
The case was the first to go to trial of more than 600 suits claiming that Glaxo hid knowledge of birth defect risks allegedly tied to Paxil. Tuesday’s award in Philadelphia’s Court of Common Pleas may pale in comparison to the $942 million in profits that Paxil generated for Glaxo last year, but the trial was closely watched as a test of Glaxo’s vulnerability. The company released a statement saying it disagreed with the verdict and would appeal. “While we sympathize with Lyam Kilker and his family, the scientific evidence does not establish that exposure to Paxil during pregnancy caused his condition,” the statement said.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]